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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT)
WITHOUT SEROTHERAPY IN CHILDREN IS ASSOCIATED WITH RAPID
CD4 + T-CELL RECONSTITUTION AND RECOVERY OF ANTI-VIRAL RE-
SPONSES
Chiesa, R., Rao, K., Hewitt, A., Qasim, W., Amrolia, P.J., Goulden, N.,
Veys, P. Great Ormond Street Hospital, London, United Kingdom
Conventional UCBT with serotherapy is characterized by a low
incidence of GvHD but delayed immune reconstitution and high in-
fection-related mortality. We evaluated early immune reconstitu-
tion, infection-related mortality and incidence of GvHD in
children undergoing unrelated UCBT without serotherapy.
13 children with a median age of 12 months (range, 1-144) un-
derwent an unrelated UCBT for SCID (7), high risk/relapsed
ALL (4) and secondary AML (2). Conditioning was myeloablative
in 11 patients, reduced intensity in 1 patient and none in 1. HLA
matching was 6/6, 5/6 and 4/6 in six, six and four cases respectively
(3 double cord infusions). GvHD prophylaxis was cyclosporine/
mycophenolate mofetil (11), cyclosporine/methylprednisolone (1)
and cyclosporine (1). The median number of nucleated, CD34+
and CD3+ cells infused was 8.8  107/kg (range, 4.7-17.72), 3.8
 105/kg (range, 1.23-11.95) and 6.1  106/kg (range, 1.9-24.45),
respectively.
Median time to myeloid and platelet engraftment was 21 (range,
13-35) and 39 (range, 32-71) days, respectively. One patient died
from conditioning related toxicity. 12 patients are alive and in remis-
sion with a median follow up of 12 months (range, 3-60). 10 patients
have full donor chimerism while 2 patients have full donor chime-
rism in the lymphoid compartment only.
The incidence of aGvHD was high (grade II n5 7; grade III-IV
n5 3) but generally responded promptly to steroids. At last fol-
low-up, 8 patients are off immunosuppression, and one developed
limited cGvHD. There was no infection-related mortality and low
incidence of viral reactivations (n5 3 adenoviraemia).
Our most striking finding was of rapid CD4 +T-cell reconstitu-
tion. The median CD3+, CD4+ and CD8+ counts within 2 months
postUCBTwas 0.83 x109cells/L (range, 0.44-2.44), 0.63 x109cells/L
(range, 0.06-1.89), and 0.15 x109cells/L (range, 0.01-1.21) respec-
tively. This contrasts to a similar group of children (7) who under-
went unrelated UCBT with serotherapy in whom the median
CD3+/CD4+/CD8+ counts at 2 months were 0.07/0.03/0.03
x109cells/L. In our cohort 5 of 9 evaluable patients had normal
CD4+ counts by 5-6 months post transplant.
Adenovirus specific T cells were detected as early as 60 days post
transplant, and all 3 cases of adenoviraemia resolved rapidly.
We conclude that unrelatedUCBTwithout serotherapy, while as-
sociated with a higher incidence of steroid-responsive aGvHD, re-
sults in rapid CD4 +T-cell reconstitution and a low incidence of
viral complications.176
ENHANCED IMMUNE RECONSTITUTION DESPITE IN VIVO LYMPHO-DE-
PLETION AS PART OF ACUTE GRAFT VS HOST DISEASE AGVHD PROPHY-
LAXIS IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTS
UHSCT
Gul, Z.1, Abdul-Hussein, M.2, Abidi, M.1, Ayash, L.1, Lum, L.1,
Chen,W.3, Uberti, J.1, Ratanatharathorn, V.1, Al-Kadhimi, Z.1 1Wayne
State University/Karmanos Cancer Center, Detroit, MI; 2Sinai Grace
Hospital, Detroit, MI; 3Karmanos Cancer Center, Detroit, MI
Background: Slow lymphocyte recovery and low immunoglobulin
levelspostUHSCTmaycontribute toworse clinical outcomes.(relapse
and survival). We reported preliminary low rates of aGVHD, infec-
tions and treatment related toxicity with the use of Thymoglobulin
(4.5 mg/kg divided doses on days -1,-2, & -3), Tacrolimus and Siroli-
mus for aGVHD prophylaxis in adult UHSCT. Here we explored
the differences in absolute lymphocyte count ALC and Immunoglob-
ulin IgG levels at three time points (days 30, 60, & 90) post transplant
in relation to a large comparable groupof historical patients at our cen-
ter treatedwithTacrolimusandMycophenolate (TM)asaGVHDpro-
phylaxis.
Methods: Analyses are made on non-censored and censored data
(for aGVHD and relapse events) in TTS vs TM groups. The
original measurements ALC & IgG are tested at each time point(30, 60, and 90 days) for group differences via the Student’s t-test.
The dichotomized measurements (thresholds of ALC at 1000/ml
and IgG at 500/ml) are compared between two groups using Fish-
er’s exact test. The difference in the linear trends of ALC and IgG
thresholds between two treatment groups is investigated using lo-
gistic model and Wald Chi-square test for interaction of day and
group.
Results:There were 25 patients on TTS and 72 on TM. The in-
cidence of aGVHD was higher in TM 77.8% compared to 24%
in TTS (P\ 0.0001). No difference in the relapse rate (12.5%
TM vs 16% TTS P 0.7354). We observed a higher mean IgG
level in TTS vs TM groups at days 60 & 90 post transplant (P
0.0558 & 0.0087), In addition to higher percentage of patients
with an IgG level. 500 mg/ml on days 30 & 90 (P 0.0358,
0.0078). When patients with aGVHD & relapse were excluded
from both groups, there was no statistical deference between
TTS & TM. Furthermore the percentage of patients with
ALC. 1000/ml in TTS nearly tripled in a linear fashion from
day 30 to day 90 (20 to 59% trend test P 0.0086 for non cen-
sored & 17% to 58% P 0.0081 for censored), while the same per-
centage nearly doubled for TM group between days 30 and 90(21
to 46% P 0.0025 for non censored & 26 to 63 P 0.0017 for cen-
sored).
Conclusion: These early results suggest that there is an enhanced
immune reconstitution in the experimental group TTS despite lym-
pho-depletion, as shown by higher IgG as well as a steep linear recov-
ery of ALC. We postulate that the decreased aGVHD in TTS
resulted in less need for additional immune suppression and hence
improved immune reconstitution.
Comparing dichotomized biomarkers between Experimental
and historical control groups on noncensored data
Control ExperimentalthPercent
above
resholdp
value thPercent
above
resholdp
valuep
valueImmunoglobulins5.500
Day 30 76% 0.3591* 96% 0.6334* 0.0358†
Day 60 78% 92% 0.2172†
Day 90 69% 100% 0.0078†
Lymphocytes5.1000 0.4332 ‡
Day 30 21% 0.0025* 20% 0.0086* 1.0000†
Day 60 47% 50% 0.3322†
Day 90 36% 59% 0.4164†† P-values from two-sided Fisher’s exact test for the difference between
two groups at each time point. * P-values from the Cochran-Armitage
Trend Test for the linear trend across 3 time points within each group
‡: P-values from theWald Chi-square test for linear trend difference be-
tween two groups177
THE ABSENCE OF VASOACTIVE INTESTINAL PEPTIDE AUGMENTS ALLO-
REACTIVITY AND THE ANTI-VIRAL RESPONSE IN A BONE MARROW
TRANSPLANT SETTING
Li, J.-M.1, Shin, K.1, Southerland, L.2, Hossain, S.1, Harris, W.1,
Waschek, J.3, Waller, E.K.1 1Winship Cancer Institute, Emory Univer-
sity, Atlanta, GA; 2Duke University, Durham, NC; 3University of Cal-
ifornia, Los Angeles, CA
Backgrounds:Vasoactive intestinal peptide (VIP) can lead to the gen-
eration of regulatory dendritic cells (DC). In this study, we used DC
and T-cells from VIP-knockout (VIP-KO) mice to investigate the ef-
fects of VIP on allogeneic and anti-viral immune responses in trans-
plant recipients.
Methods: 5 106 BM and 1, 3, 8 106 splenocytes (SP) from VIP-
KO and WT donors, single VIP-KO donors, single WT donors, or
single VIP-heterozygous donors were transplanted in B6/ B10BR
alloBMT and B6/ B6 synBMT models. Survival and GvHD were
